AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)

AVAN 10.04

0.0%

Jun 12 9:41 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (494)	7/15/2004 5:11:58 PM
From: rrufff	of 513

Hi Tuck - lots of mention today on AVAN Here's from the Street.com Markets : Stocks In Motion Health Stocks in Motion Page 2 Avant Immunotherapeutics (AVAN:Nasdaq - commentary - research) rose after the company announced that its Rotarix vaccine was approved by Mexican health officials. The drug was developed in partnership with GlaxoSmithKline (GSK:NYSE - commentary - research) and is used to prevent gastroenteritis caused by rotavirus infection. Rotavirus infection is the leading cause of severe diarrhea and vomiting in infants and children between the ages of 3 and 24 months. Worldwide, rotaviruses account for about 138 million cases of infantile gastroenteritis each year, resulting in about 440,000 deaths a year. Shares of Avant Immunotherapeutics traded up 28 cents, or 11.9%, to $2.63. Also was mentioned in Briefing.com in connection with The House of Representatives approving the $5.6 bln anti-terrorism initiative Project Bioshield.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next